Results 181 to 190 of about 195,942 (257)

S'Wipe: user-friendly stool collection for high-throughput gut metabolomics and multi-omics. [PDF]

mSystems
Moradi D, Lotfi A, Melnik AV, Smirnov A, Pobozhev K, Monahan H, Kopylova E, Zhou Y, Aksenov AA.   +8 more
europepmc   +1 more source

The Role of Microbiota Metabolites Propionic Acid, p‐Cresol, and 4‐Ethylphenyl Sulfate in Autism Susceptibility: A Systematic Review

Autism Research, EarlyView.
ABSTRACT The etiopathogenesis of Autism Spectrum Disorder (ASD) encompasses complex interactions between genetic and environmental risk factors. The high prevalence of gastrointestinal disorders in autistic individuals has propelled a growing interest in the possible involvement of gut dysbiosis in ASD pathogenesis.
Laura Sandoni, Lisa Asta, Nicole Giompaolo, Rinvil Renaldi, Alberto Amaretti, Maddalena Rossi, Antonio M. Persico   +6 more
wiley   +1 more source

Impact of transport source (dairy farms vs. collection center) and post-arrival housing in combination with prophylactic antibiotic treatment on performance, lung health and microbiota of veal calves. [PDF]

Front Vet Sci
Marcato F, Schokker D, Stockhofe-Zurwieden N, Gort G, Jansen CA, Wolthuis-Fillerup M, Osaro John J, Strappini AC, Gilbert MS, Gerrits WJJ, Van Reenen CG.   +10 more
europepmc   +1 more source

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

British Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen, Fariha Balouch, Claire Reilly, Christopher Burgess, Peter Lewindon   +4 more
wiley   +1 more source

Effects of L-selenomethionine supplementation on nutrient digestibility and metabolism, antioxidant capacity, hormone levels, and fecal microbiota diversity in pregnant Yili mares during mid- to late gestation. [PDF]

BMC Vet Res
Li M, Lin J, Ma C, Wei G, Hu Q, Li X.
europepmc   +1 more source

Assessing transporter‐mediated rifampin–linezolid interaction using physiologically‐based pharmacokinetic modelling

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The study aims to develop a physiologically‐based pharmacokinetic (PBPK) model to quantitatively evaluate the role of ATP‐binding cassette sub‐family B member 1 (ABCB1) and ATP‐binding cassette super‐family G member 2 (ABCG2) in the drug–drug interaction (DDI) between rifampin and linezolid and to predict the impact of high‐dose rifampin ...
Hoang Dat Nguyen, Vinh Hoa Pham, Richard M. Hoglund, Joel Tarning, Junjie Ding   +4 more
wiley   +1 more source

First Report of Fascioliasis of Ruminants in the Kharaa River Basin and Identification of Snail Hosts in Mongolia. [PDF]

Vet Med Int
Sukhbaatar L, Cleary NG, Tserennyam D, Enkherdene E, Boldbaatar C, Sambuu G, Tserendorj M, Sukhbaatar O, Zayat B, von Fricken ME.   +9 more
europepmc   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source

Identifying determinants of bacterial fitness in a model of human gut microbial succession [PDF]

, 2020
Cheng, Jiye, Feng, Lihui, Gordon, Jeffrey I., Griffin, Nicholas W., Hibberd, Matthew C., Leyn, Semen A., Osterman, Andrei L., Peng, Yangqing, Raman, Arjun S., Rodionov, Dmitry A.   +9 more
core   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source